IP Library Granted Patent US 9,408,927
Granted Patent B2
US 9,408,927 · App. 12/919,600 · Granted Aug 9, 2016

Contrast agents for applications including perfusion imaging

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,408,927
App. No.
12/919,600
Granted
Aug 9, 2016
Kind
B2
Abstract

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

Claims (28)

1. A method of imaging at least a portion of the central nervous system (CNS) in a subject, comprising:

administering to the subject a contrast agent having a structure as in Formula (II),

wherein:

J is selected from N(R 27 ), S, O, C(═O), C(═O)O, NHCH 2 CH 2 O, a bond, or C(═O)N(R 27 );

K and L, when present, are independently selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety, each of which is optionally substituted;

M is selected from alkoxyalkyl or alkyloxy, each of which is optionally substituted, or

L and M, together with the atom to which they are attached, form a ring, optionally substituted;

Q is halo or haloalkyl;

n is 0, 1, 2, or 3;

R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 are independently selected from hydrogen, alkyl, optionally substituted, and an imaging moiety;

R 29 is alkyl, optionally substituted; and

Y is carbon or oxygen; provided that when Y is oxygen, K and L are absent and M is alkoxyalkyl, optionally substituted,

wherein at least one imaging moiety is present in Formula (II); and

scanning the subject using diagnostic imaging to produce an image of at least a portion of the CNS.

2. The method as in claim 1 , wherein the method of imaging at least a portion of the CNS in the subject comprises imaging perfusion in the brain of the subject.

3. A method as in claim 1 , wherein the image is used in the diagnosis of a subject.

4. A method as in claim 3 , wherein the diagnosis is a diagnosis of a CNS disorder or condition.

5. A method as in claim 1 , wherein the image is used to determine the stage of a disease.

6. A method as in claim 5 , wherein the disease is a CNS disorder or condition.

7. A method as in claim 1 , further comprising selecting a treatment for a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the CNS of the subject.

8. A method as in claim 1 , further comprising evaluating a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the CNS of the subject.

9. A method as in claim 2 , further comprising selecting a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the brain.

10. A method as in claim 2 , further comprising evaluating a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the brain.

11. A method as in claim 1 , wherein J is O, Q is Cl, and R 29 is C 1 -C 6 alkyl.

12. A method as in claim 1 , wherein each of K and L is hydrogen, Y is carbon, and M is alkoxyalkyl or alkyloxy, optionally substituted with an imaging moiety.

13. A method as in claim 1 , wherein the imaging moiety is 18 F.

14. A method as in claim 1 , wherein M is alkoxyalkyl or alkyloxy substituted with an imaging moiety.

15. A method as in claim 1 , wherein the contrast agent is:

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 062047/0925 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Jun 28, 2019
From: LANTHEUS MEDICAL IMAGING, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 049628/0001 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2019
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 049623/0123 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS Recorded Mar 30, 2017
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: LANTHEUS HOLDINGS, INC.; LANTHEUS MEDICAL IMAGING, INC.; LANTHEUS MI REAL ESTATE, LLC
Reel/Frame 042115/0715 →
NOTICE OF SUCCESSION OF AGENCY Recorded Mar 30, 2017
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 042115/0769 →
SECURITY AGREEMENT Recorded Jun 30, 2015
From: LANTHEUS MEDICAL IMAGING, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 036013/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: ROBINSON, SIMON P.; CASEBIER, DAVID S.; YU, MING; KAGAN, MIKHAIL; LAZEWATSKY, JOEL
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 030739/0467 →
AMENDMENT NUMBER ONE TO GRANT OF A SECURITY INTEREST - PATENTS Recorded Jul 3, 2013
From: LANTHEUS MI INTERMEDIATE, INC.; LANTHEUS MEDICAL IMAGING, INC.; LANTHEUS MI REAL ESTATE, LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030747/0814 →